---
title: 'Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term
  Assessment Study'
date: '2023-11-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38019503/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231129170911&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS AND RELEVANCE: Among approximately one-quarter of the original
  participants, use of short-term topical atropine eye drops ranging from 0.01% to
  1.0% for a duration of 2 to 4 years during childhood was not associated with differences
  in final refractive errors 10 to 20 years after treatment. There was no increased
  incidence of treatment or myopia-related ocular complications in the 1% atropine-treated
  group vs the placebo group. These findings may affect the design of future ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: Among approximately one-quarter of the original participants, use of short-term topical atropine eye drops ranging from 0.01% to 1.0% for a duration of 2 to 4 years during childhood was not associated with differences in final refractive errors 10 to 20 years after treatment. There was no increased incidence of treatment or myopia-related ocular complications in the 1% atropine-treated group vs the placebo group. These findings may affect the design of future ...